RNA-based Immunization Delivery Systems for Environmental Remediation
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of RNA-based immunization delivery systems to tackle environmental pollutants and pests in various industries, including wastewater treatment, bioremediation, agriculture, and industrial emissions monitoring.
Background and Problem Solved
The original patent addressed the delivery of RNA for immunization in the field of non-viral delivery. However, the patent's scope was limited to immunizing animals. The new inventive concept solves the problem of applying RNA-based immunization delivery systems to entirely new fields, addressing the pressing issue of environmental pollution and its devastating consequences.
Detailed Description of the Inventive Concept
The RNA-based immunization delivery system is adapted to trigger an immune response against pollutants in wastewater, contaminated soil, agricultural pests, and industrial emissions. The system comprises RNA molecules designed to stimulate an immune response, which are then delivered using liposomes or other non-viral vectors. The RNA molecules can be modified to enhance stability, efficacy, and specificity. The system can be integrated into existing infrastructure, such as wastewater treatment plants or agricultural systems, to provide a novel solution for environmental remediation.
Novelty and Inventive Step
The new claims introduce a novel application of RNA-based immunization delivery systems to environmental remediation, which is non-obvious and unforeseen from the original patent. The inventive step lies in the adaptation of the core technology to address a completely different problem domain, requiring significant modifications and innovations to the original system.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of RNA molecules, such as siRNA or miRNA, or exploring various delivery methods, such as nanoparticles or viral vectors. Variations could also involve targeting different types of pollutants or pests, or integrating the system with existing technologies, such as sensors or monitoring systems.
Potential Commercial Applications and Market
The RNA-based immunization delivery system for environmental remediation has vast commercial potential, with applications in wastewater treatment, bioremediation, agriculture, and industrial emissions monitoring. The market size is significant, with the global environmental remediation market projected to reach billions of dollars in the coming years. The inventive concept has the potential to disrupt traditional methods of environmental remediation and provide a novel, effective, and sustainable solution.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and molecular biology, specifically RNA delivery systems and immunization technologies, with expertise in non-viral vector design, RNA molecule modification, and targeted biological response mechanisms
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in biotechnology or molecular biology, experienced in RNA engineering, drug delivery systems, and immunological techniques, familiar with liposomal delivery methods and nucleic acid modification strategies
Obviousness Rationale
A PHOSITA would recognize that the core RNA delivery technology from the source patent can be readily adapted to environmental applications by modifying the target molecules and response mechanism. The fundamental principles of RNA-based immunization are transferable across different domains, with predictable modifications to achieve specific biological responses. The PTD demonstrates a straightforward extension of existing RNA delivery technologies to novel problem domains, utilizing well-established molecular engineering techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,562 |
|---|---|
| Title | Delivery of RNA to trigger multiple immune pathways |
| Assignee(s) | GlaxoSmith Kline Biologicals S.A. |